Johnson & Johnson 2Q Revenues: $17.9 billion (+9%) 2Q Earnings: $3.8 billion (+172%) YTD Revenues: $35.4 billion (+9%) YTD Earnings: $7.3 billion (+38%) Comments: Worldwide Pharmaceutical sales were $7.0 billion in the quarter, up 12%, driven by sales of Remicade and Simponi, Stelara, Invega Sustenna/Xeplion, Velcade and Prezista. Domestic sales increased 9% and international sales increased 14%. Worldwide Consumer sales were $3.7 billion, up 1%. Results in the quarter included the gain...